Unclaimed brand
JOURNAVX is an oral medication to treat adults with moderate-to-severe acute pain, including postoperative pain. See Important Safety Information and Patient Information.
Liking this brand profile? Share this page
No logo added yet.
Hex Code
Color name
RGB
HSL
CMYK
#876CD5
True V
135, 108, 213
255, 56, 63
37, 49, 0, 16
#2B034D
Cherry Pie
43, 3, 77
272, 93, 16
44, 96, 0, 70
#E35FB4
Deep Blush
227, 95, 180
321, 70, 63
0, 58, 21, 11
JOURNAVX™ (suzetrigine) is a first-in-class, FDA-approved, oral non-opioid prescription pain medication developed by Vertex Pharmaceuticals, approved on January 30, 2025 — marking the first new class of acute pain treatment approved by the FDA in over 20 years. A highly selective NaV1. 8 pain signal inhibitor, JOURNAVX works by blocking pain signals in the peripheral nervous system before they reach the brain — delivering effective relief for adults with moderate-to-severe acute pain caused by surgery, injury, or accident, with no evidence of addictive potential.
The journavxpap. com portal specifically serves as the Patient Assistance Program gateway, helping eligible patients access JOURNAVX regardless of their ability to pay
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
Suzetrigine prescription medicine
NaV1.8 pain-signal inhibition
Nonopioid acute pain treatment
Postoperative pain medicine
